Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246033 | 0.96 | F10 (0.52) | F10KLKB1ACKR3 | |
| SCHEMBL8225992 | 0.91 | F10 (0.61) | F10KLKB1ACKR3DHPS | |
| SCHEMBL1245688 | 0.88 | F10 (0.46) | F10KLKB1ACKR3 | |
| SCHEMBL3613837 | 0.88 | F10 (0.58) | F10KLKB1ACKR3 | |
| SCHEMBL8225168 | 0.85 | F10 (0.51) | F10KLKB1ACKR3DHPSCYP3A4 | |
| SCHEMBL8225326 | 0.85 | F10 (0.51) | F10KLKB1ACKR3CYP3A4CYP2C8 | |
| SCHEMBL4245786 | 0.84 | F10 (0.41) | F10DHPS | |
| SCHEMBL1243692 | 0.83 | F10 (0.65) | F10ACKR3DHPS | |
| SCHEMBL8230473 | 0.83 | F10 (0.47) | F10KLKB1ACKR3 | |
| SCHEMBL8220885 | 0.82 | F10 (0.46) | F10KLKB1ACKR3CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2007137793-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | DPYD, QDPR, DHPS | F10 1315/4885KLKB1 1626/4885ACKR3 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.